Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve(TM) Antimicrobial Wound Gel
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(75)
•••
Comment by francoisl13on Aug 28, 2024 9:39am
32 Views
Post# 36199140

RE:RE:New Press Release - Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve(TM)&#xA0;Antimicrobial Wound Gel

RE:RE:New Press Release - Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve(TM)&#xA0;Antimicrobial Wound GelTo the contrary, working with small local distributor will most likely give 'Revyve' a high priority at those distributor while a large one might just lost sight of some of the product they have to distribute.
I agreee that it will likely be a little harder to manage. What I really like is the pace at which they are signing agreement, it bodes well. 
Now, let's get Health Canada final approval and sign a distribution agreement in Australia/New Zealand.
GLTA!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities